Alterola Biotech Inc
Alterola Biotech, Inc., a pharmaceutical company, engages in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. It focuses on the development of regulated human and animal health pharmaceuticals and regulated food products; production of active pharmaceutical ingredients and food-grade ingredients; and formulation and drug delivery for improved bioavailabil… Read more
Alterola Biotech Inc (ABTI) - Total Assets
Latest total assets as of September 2024: $1.36 Million USD
Based on the latest financial reports, Alterola Biotech Inc (ABTI) holds total assets worth $1.36 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Alterola Biotech Inc - Total Assets Trend (2009–2024)
This chart illustrates how Alterola Biotech Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Alterola Biotech Inc - Asset Composition Analysis
Current Asset Composition (March 2024)
Alterola Biotech Inc's total assets of $1.36 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 72.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $1.01K | 27.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Alterola Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alterola Biotech Inc's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2009.
- Cash Position: Cash and equivalents constituted 72.5% of total assets in 2024, down from 100.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 27.6% of total assets.
Alterola Biotech Inc Competitors by Total Assets
Key competitors of Alterola Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Alterola Biotech Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Alterola Biotech Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Alterola Biotech Inc is currently not profitable relative to its asset base.
Alterola Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.32 | 0.08 | 0.08 |
| Quick Ratio | 0.32 | 0.08 | 0.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.47 Million | $ -2.32 Million | $ -228.40K |
Alterola Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Alterola Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.52 |
| Latest Market Cap to Assets Ratio | 164.78 |
| Asset Growth Rate (YoY) | -100.0% |
| Total Assets | $3.66K |
| Market Capitalization | $603.58K USD |
Valuation Analysis
Premium Asset Valuation: The market values Alterola Biotech Inc's assets at a significant premium ( 164.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Alterola Biotech Inc's assets decreased by 100.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Alterola Biotech Inc (2009–2024)
The table below shows the annual total assets of Alterola Biotech Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-03-31 | $3.66K | -99.97% |
| 2023-09-30 | $12.38 Million | 0.00% |
| 2023-03-31 | $12.38 Million | +2.05% |
| 2022-09-30 | $12.13 Million | 0.00% |
| 2022-03-31 | $12.13 Million | +79307.85% |
| 2021-09-30 | $15.27K | 0.00% |
| 2021-03-31 | $15.27K | -69.90% |
| 2020-09-30 | $50.74K | +232.23% |
| 2020-03-31 | $15.27K | +3.60% |
| 2019-09-30 | $14.74K | +470.73% |
| 2018-09-30 | $2.58K | 0.00% |
| 2018-03-31 | $2.58K | -- |
| 2017-09-30 | $0.00 | -- |
| 2016-09-30 | $2.58K | -68.93% |
| 2016-03-31 | $8.31K | 0.00% |
| 2015-09-30 | $8.31K | +34.10% |
| 2015-03-31 | $6.20K | -78.73% |
| 2014-09-30 | $29.15K | 0.00% |
| 2014-03-31 | $29.15K | +370.19% |
| 2013-09-30 | $6.20K | -78.04% |
| 2011-03-31 | $28.23K | 0.00% |
| 2010-09-30 | $28.23K | +290.75% |
| 2010-03-31 | $7.22K | 0.00% |
| 2009-09-30 | $7.22K | -- |